Havn Life Sciences Stock Fundamentals
| HAVLF Stock | USD 0.01 0.0002 4.00% |
HAVN Life Sciences fundamentals help investors to digest information that contributes to HAVN Life's financial success or failures. It also enables traders to predict the movement of HAVN Pink Sheet. The fundamental analysis module provides a way to measure HAVN Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HAVN Life pink sheet.
HAVN |
HAVN Life Sciences Company Operating Margin Analysis
HAVN Life's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current HAVN Life Operating Margin | (7.64) % |
Most of HAVN Life's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HAVN Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, HAVN Life Sciences has an Operating Margin of -7.6356%. This is 78.23% lower than that of the Healthcare sector and 93.19% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 38.58% higher than that of the company.
HAVN Life Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HAVN Life's current stock value. Our valuation model uses many indicators to compare HAVN Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HAVN Life competition to find correlations between indicators driving HAVN Life's intrinsic value. More Info.HAVN Life Sciences is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HAVN Life's earnings, one of the primary drivers of an investment's value.HAVN Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HAVN Life's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of HAVN Life could also be used in its relative valuation, which is a method of valuing HAVN Life by comparing valuation metrics of similar companies.HAVN Life is rated # 4 in operating margin category among its peers.
HAVN Fundamentals
| Return On Equity | -2.39 | |||
| Return On Asset | -0.37 | |||
| Operating Margin | (7.64) % | |||
| Current Valuation | 626.96 K | |||
| Shares Outstanding | 8.47 M | |||
| Shares Owned By Insiders | 2.77 % | |||
| Price To Book | 0.21 X | |||
| Price To Sales | 0.98 X | |||
| Revenue | 276.47 K | |||
| Gross Profit | 89.69 K | |||
| EBITDA | (21.8 M) | |||
| Net Income | (22.44 M) | |||
| Cash And Equivalents | 112.42 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 561.84 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 0.18 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (7.88 M) | |||
| Earnings Per Share | (0.15) X | |||
| Beta | 0.0335 | |||
| Market Capitalization | 415.27 K | |||
| Total Asset | 4.06 M | |||
| Z Score | -16.5 | |||
| Net Asset | 4.06 M |
About HAVN Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HAVN Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HAVN Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HAVN Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The company was incorporated in 2020 and is headquartered in Richmond, Canada. Havn Life operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in HAVN Pink Sheet
HAVN Life financial ratios help investors to determine whether HAVN Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HAVN with respect to the benefits of owning HAVN Life security.